Cart summary

You have no items in your shopping cart.

Salicoside

SKU: orb1226392

Description

Salicin is a phenol β-glycosid produced from willow bark that shows anti-inflammatory effects.(In Vitro):Significant down regulation of PGE2, the enzymatic product of COX2, to 76% in lysate and 70% in supernatant is observed with Salicin 10 μM treatment in COLO cells when compare to the COLO control. This is accompanied with a minimal COX1 inhibition to 91% of the CCD control on the genetic level. Treatment with Salicin 1 μM decreases colon cancer cell proliferation rates from 144% to 113% at 24 hours and 187% to 130% at 48 hours, with 10 μM decreasing proliferation rates to 108% at 24 hours and 119% at 48 hours. The concentrations of TNF-α, IL-1β and IL-6 of LPS-induced cells pretreated with 0.07, 0.14 and 0.28 μM Salicin are significant reduced compare with LPS group.(In Vivo):Salicin (D(-)-Salicin) (35, 70, 140 μM) markedly inhibits the LPS-induced pathological changes. MPO activity in LPS-induced lung tissue is significantly increased compare with control group. However, Salicin (35, 70, 140 μM) markedly inhibits this change. Pretreatment with Salicin inhibits LPS-induced activation of JNK, ERK, p38/MAPK and p65 in a dose-dependent manner.

Images & Validation

Key Properties

CAS Number138-52-3
MW286.28
Purity>98% (HPLC)
FormulaC13H18O7
SMILESO[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1OC2=CC=CC=C2CO
TargetCOX
SolubilityWater: 24 mg/mL (83.83 mM); DMSO: 57 mg/mL (199.1 mM)

Bioactivity

In Vivo
Salicin (D(-)-Salicin) (35, 70, 140 μM) markedly inhibits the LPS-induced pathological changes. MPO activity in LPS-induced lung tissue is significantly increased compared with control group. However, Salicin (35, 70, 140 μM) markedly inhibits this change. Pretreatment withSalicin inhibits LPS-induced activation of JNK, ERK, p38/MAPK and p65 in a dose-dependent manner.
In Vitro
Significant down regulation of PGE2, the enzymatic product of COX2, to 76% in lysate and 70% in supernatant is observed with Salicin 10 μM treatment in COLO cells when compare to the COLO control. This is accompanied with a minimal COX1 inhibition to 91% of the CCD control on the genetic level. Treatment with Salicin 1 μM decreases colon cancer cell proliferation rates from 144% to 113% at 24 hours and 187% to 130% at 48 hours, with 10 μM decreasing proliferation rates to 108% at 24 hours and 119% at 48 hours. The concentrations of TNF-α, IL-1β and IL-6 of LPS-induced cells pretreated with 0.07, 0.14 and 0.28 μM Salicin are significant reduced compare with LPS group.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

NSC 5751 | D-(-)-Salicin

Similar Products

  • Salicin [orb1310611]

    98.79%

    138-52-3

    286.28

    C13H18O7

    1 ml x 10 mM (in DMSO), 10 g
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Salicoside (orb1226392)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%